Please login to the form below

Not currently logged in
Email:
Password:

PvP Biologics

This page shows the latest PvP Biologics news and features for those working in and with pharma, biotech and healthcare.

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Takeda buys coeliac disease partner PvP Biologics after phase 1 win

Deal includes upfront payment plus up to $330m in milestones. Takeda’s ‘build to buy’ strategy of partnering has resulted in a takeover deal for coeliac disease drug developer PvP Biologics. ... The approach taken with the PvP partnership mirrors

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    It proved to be a very busy month for Takeda with the company paying $35m to PvP Biologics for KumaMax for coeliac disease which is in preclinical development.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...